At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 554 enrolled
Drug / intervention
Desmopressin Meltdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
In Brief
A Phase 3 clinical trial evaluating Desmopressin Melt for Nocturia. Completed, enrolled 554 participants across 73 sites in 2 countries.
Detailed Summary
The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedFeb 2008
Primary CompletionMay 2010
TodayJul 2026
First PostedFeb 14, 2008
Enrollment StartDec 1, 2007
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.4 years ago
Interventions
Desmopressin Meltdrug
An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.